JP2014506448A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014506448A5 JP2014506448A5 JP2013549784A JP2013549784A JP2014506448A5 JP 2014506448 A5 JP2014506448 A5 JP 2014506448A5 JP 2013549784 A JP2013549784 A JP 2013549784A JP 2013549784 A JP2013549784 A JP 2013549784A JP 2014506448 A5 JP2014506448 A5 JP 2014506448A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- antigen
- binding fragment
- cdr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012634 fragment Substances 0.000 claims 41
- 239000000427 antigen Substances 0.000 claims 34
- 102000036639 antigens Human genes 0.000 claims 34
- 108091007433 antigens Proteins 0.000 claims 34
- 239000003146 anticoagulant agent Substances 0.000 claims 12
- 229940127219 anticoagulant drug Drugs 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 230000003278 mimic effect Effects 0.000 claims 5
- 238000000338 in vitro Methods 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 108091035707 Consensus sequence Proteins 0.000 claims 2
- 229940122388 Thrombin inhibitor Drugs 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000014508 negative regulation of coagulation Effects 0.000 claims 2
- 229960001148 rivaroxaban Drugs 0.000 claims 2
- KGFYHTZWPPHNLQ-AWEZNQCLSA-N rivaroxaban Chemical compound S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2C(COCC2)=O)C1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 claims 2
- 239000003868 thrombin inhibitor Substances 0.000 claims 2
- OFJRNBWSFXEHSA-UHFFFAOYSA-N 2-(3-amino-1,2-benzoxazol-5-yl)-n-[4-[2-[(dimethylamino)methyl]imidazol-1-yl]-2-fluorophenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide Chemical compound CN(C)CC1=NC=CN1C(C=C1F)=CC=C1NC(=O)C1=CC(C(F)(F)F)=NN1C1=CC=C(ON=C2N)C2=C1 OFJRNBWSFXEHSA-UHFFFAOYSA-N 0.000 claims 1
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 claims 1
- 238000009007 Diagnostic Kit Methods 0.000 claims 1
- HGVDHZBSSITLCT-JLJPHGGASA-N Edoxaban Chemical compound N([C@H]1CC[C@@H](C[C@H]1NC(=O)C=1SC=2CN(C)CCC=2N=1)C(=O)N(C)C)C(=O)C(=O)NC1=CC=C(Cl)C=N1 HGVDHZBSSITLCT-JLJPHGGASA-N 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 229940123583 Factor Xa inhibitor Drugs 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 229960003886 apixaban Drugs 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 229950011103 betrixaban Drugs 0.000 claims 1
- XHOLNRLADUSQLD-UHFFFAOYSA-N betrixaban Chemical compound C=1C=C(Cl)C=NC=1NC(=O)C1=CC(OC)=CC=C1NC(=O)C1=CC=C(C(=N)N(C)C)C=C1 XHOLNRLADUSQLD-UHFFFAOYSA-N 0.000 claims 1
- 239000003130 blood coagulation factor inhibitor Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229960003850 dabigatran Drugs 0.000 claims 1
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 claims 1
- 229960000622 edoxaban Drugs 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 229950010535 razaxaban Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11151410.5 | 2011-01-19 | ||
| EP11151410 | 2011-01-19 | ||
| PCT/EP2012/050595 WO2012098089A1 (en) | 2011-01-19 | 2012-01-17 | Binding proteins to inhibitors of coagulation factors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014506448A JP2014506448A (ja) | 2014-03-17 |
| JP2014506448A5 true JP2014506448A5 (https=) | 2015-03-05 |
Family
ID=45491612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013549784A Pending JP2014506448A (ja) | 2011-01-19 | 2012-01-17 | 凝固因子の阻害剤に対する結合タンパク質 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20140050743A1 (https=) |
| EP (1) | EP2665751A1 (https=) |
| JP (1) | JP2014506448A (https=) |
| CN (1) | CN103619883A (https=) |
| AR (1) | AR084886A1 (https=) |
| CA (1) | CA2824885A1 (https=) |
| WO (1) | WO2012098089A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017237543B2 (en) * | 2016-03-23 | 2020-02-06 | Institut Pasteur Korea | Antibody that binds to envelope glycoprotein of severe fever with thrombocytopenia syndrome virus, and use for same |
| GB201618432D0 (en) * | 2016-11-01 | 2016-12-14 | Matn Scient Ltd | Detection and treatment of demyelinating diseases |
| EP3577140A1 (en) | 2017-02-01 | 2019-12-11 | Novo Nordisk A/S | Procoagulant antibodies |
| NL2036011B1 (en) | 2023-10-12 | 2025-04-30 | Synapse Res Institute | Molecules for reversing anti-coagulant activity of direct oral anticoagulants |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| ES2176484T3 (es) | 1995-08-18 | 2002-12-01 | Morphosys Ag | Bancos de proteinas/(poli)peptidos. |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| ZA985247B (en) | 1997-06-19 | 1999-12-17 | Du Pont Merck Pharma | Guanidine mimics as factor Xa inhibitors. |
| DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
| WO2001064642A2 (en) | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| US6669937B2 (en) * | 2000-04-20 | 2003-12-30 | The Board Of Trustees Of The University Of Arkansas | Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs |
| RU2319699C2 (ru) | 2001-06-20 | 2008-03-20 | Дайити Санкио Компани, Лимитед | Производные диаминов |
| WO2003000657A1 (en) | 2001-06-20 | 2003-01-03 | Daiichi Pharmaceutical Co., Ltd. | Diamine derivatives |
| CN104744461A (zh) | 2001-09-21 | 2015-07-01 | 百时美施贵宝公司 | 含有内酰胺的化合物及其衍生物作为Xa因子的抑制剂 |
| DE102007028320A1 (de) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
| DE102007028319A1 (de) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
| US8359965B2 (en) | 2007-09-17 | 2013-01-29 | Oxford J Craig | Apparatus and method for broad spectrum radiation attenuation |
| EP2915564B1 (en) | 2007-09-28 | 2020-11-04 | Portola Pharmaceuticals, Inc. | Antidotes for factor XA inhibitors and methods of using the same |
| MX2011004907A (es) * | 2008-11-14 | 2011-07-29 | Portola Pharm Inc | Antidotos para inhibidores del factor xa y metodos para el uso de los mismos en combinacion con agentes de coagulacion de sangre. |
| AR079944A1 (es) * | 2010-01-20 | 2012-02-29 | Boehringer Ingelheim Int | Anticuerpo neutralizante de la actividad de un anticoagulante |
-
2012
- 2012-01-17 CN CN201280014817.3A patent/CN103619883A/zh active Pending
- 2012-01-17 JP JP2013549784A patent/JP2014506448A/ja active Pending
- 2012-01-17 EP EP12700348.1A patent/EP2665751A1/en not_active Withdrawn
- 2012-01-17 CA CA2824885A patent/CA2824885A1/en not_active Abandoned
- 2012-01-17 WO PCT/EP2012/050595 patent/WO2012098089A1/en not_active Ceased
- 2012-01-17 US US13/980,431 patent/US20140050743A1/en not_active Abandoned
- 2012-01-18 AR ARP120100166A patent/AR084886A1/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120414T1 (el) | Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους | |
| RU2015129813A (ru) | Антитела, которые связываются с лигандом запрограммированной клеточной смерти 1 (pd-l1) | |
| ES2641294T3 (es) | Nuevo anticuerpo para el diagnóstico y/o el pronóstico del cáncer | |
| RU2018132044A (ru) | Антитела против тау | |
| AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
| BR112013008765B8 (pt) | Anticorpos monoclonais anti-tau humano isolados ou um fragmento de ligação à tau dos mesmos, métodos de preparação dos mesmos, polinucleotídeo ou polinucleotídeos, vetor ou vetores, composição, método in vitro de diagnóstico ou monitoramento da progressão de uma tauopatia neurodegenerativa em um indivíduo humano, método in vitro para diagnosticar uma tauopatia neurodegenerativa em um indivíduo humano, e kit útil para o diagnóstico de uma tauopatia neurodegenerativa | |
| EA201790757A1 (ru) | Связывающие антиген cd27l белки | |
| JP2014061000A5 (https=) | ||
| CY1118540T1 (el) | Μονοκλωνικα αντισωματα | |
| EA201400568A1 (ru) | Альбуминсвязывающие антитела и их связывающие фрагменты | |
| JP2012143232A5 (https=) | ||
| RU2012142230A (ru) | Антитела против csf-1r человека и их применение | |
| TR201909531T4 (tr) | Anti-il-17 anti̇korlari kullanilarak anki̇lozan spondi̇li̇t tedavi̇ etme yöntemleri̇ | |
| JP2020524510A5 (https=) | ||
| MX2011008843A (es) | Anticuerpos humanizados que se unen a cd19 y sus usos. | |
| WO2012088247A3 (en) | Anti-c5/c5a/c5adesr antibodies and fragments | |
| EA201790816A1 (ru) | Антитела, которые связываются с ccr6, и варианты применения указанных антител | |
| JP2014534237A5 (https=) | ||
| JP2020507578A5 (https=) | ||
| RU2015121617A (ru) | Способы лечения заболеваний, ассоциированных с s. aureus | |
| JP2014506448A5 (https=) | ||
| EA201270701A1 (ru) | Ингибирующие металлопротеины антитела | |
| JP2017506505A5 (https=) | ||
| RU2015154792A (ru) | Выделенный антиген лейкоцидина Staphylococcus aureus, антитело, специфически связывающееся с субъединицей LukGH и способ определения связывания или токсичности двухкомпонентного цитолизина LukGH Staphylococcus aureus | |
| FI4031569T3 (fi) | Kantasolutekijän vasta-aineet ja niiden käyttömenetelmät |